天宜上佳(688033.SH)中標約2.33億元的鐵路運營物資聯合採購項目
格隆匯12月18日丨天宜上佳(688033.SH)公佈,公司於2019年12月17日收到中國鐵路建設投資公司簽發的《中標通知書》,通知公司為鐵路運營物資聯合採購項目(動車組閘片)“標段號5、標段號7、標段號9”中標單位。
此次中標總金額約2.33億元(含税),項目收入會在合同履行期間確認;截至目前合同尚未簽訂,預計不會對2019年財務狀況及經營成果產生影響。如該項目簽訂正式合同並順利實施,在項目執行期間將會對公司業務發展及經營業績產生積極影響。此次項目中標屬於國鐵集團聯合採購招標,系公司主要銷售模式之一,屬於日常經營行為,預計不會導致2020年公司營業收入出現大幅波動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.